Objective: Circulating leptin, the product of the ob gene, is known to be closely correlated with adipose tissue mass, but it is also subject to short-term regulation by a variety of hormones including catecholamines. The aim of this study was to investigate the contribution of the three b-adrenergic receptors to leptin secretion from cultured human adipocytes. Design and methods: The model of in vitro differentiated human subcutaneous adipocytes was used in this study. The presence of the b-adrenoceptor subtypes was studied by RT-PCR. The functional role of the receptor subtypes was determined by stimulation of lipolysis by selective b-adrenergic agonists and by measuring glycerol release. Leptin secretion into the medium of cultured human adipocytes from young normal-weight females was measured by radioimmunoassay. Results and conclusion: In a ®rst set of experiments, the expression of the three b-adrenergic receptor subtypes in cultured human adipocytes was demonstrated. To test their functional activity, the effect of the b-adrenoceptor agonists isoproterenol (non-selective agonist), dobutamine (b 1 -selective), fenoterol (b 2 -selective) and the b 3 -selective agonists BRL 37344 and CGP 12177 was studied. All agonists exhibited a dose-and time-dependent stimulation of glycerol release into the medium in a rather uniform manner. Isoproterenol rapidly reduced leptin secretion from cultured subcutaneous adipocytes in a dose-dependent fashion. Incubation with 10 À6 mol/l isoproterenol for 24 h resulted in a reduction of the leptin concentration by 48% (P < 0.01). A similar, but less pronounced suppressing effect was seen for dobutamine and fenoterol, whereas both BRL 37344 and CGP 12177 were not effective. These data provide evidence that catecholamines are able to suppress leptin release from differentiated human adipocytes, supporting the concept that leptin secretion is acutely regulated by surrounding hormones. This inhibition is obviously mediated via b 1 -and b 2 -adrenergic receptors.
Introduction
Leptin is the product of the recently discovered ob gene, which is mainly expressed by white and brown adipocytes (1) . This protein is secreted into the circulation and after passing the blood±brain barrier is involved in the central regulation of food intake and energy expenditure (2±4). Although circulating serum leptin levels are closely correlated with adipose tissue mass (5), it is now well known that leptin is also subject to short-term regulation by metabolic and hormonal factors (6±8).
It was originally reported by Trayhurn and coworkers that exposure of mice to cold is followed by a rapid decrease of ob mRNA levels (9) . The results of their study also suggested that this inhibition is mediated by an increase in catecholamine secretion. This observation was con®rmed in a number of subsequent studies in various animal models of obesity and under a variety of experimental conditions (10±16). In rodents, the suppression of leptin was mainly due to an activation of b 3 -adrenergic receptors (13±16).
There is now the ®rst evidence from in vitro and clinical studies for a suppressive effect of catecholamines on leptin secretion in humans (17±23), although some discrepancies remain not fully resolved (24, 25) . However, to date, it is still unde®ned which speci®c adrenoceptor subtypes are responsible for the inhibition of leptin release from human adipocytes.
It was the aim of this study to investigate the contribution of the three b-adrenergic receptor subtypes to the regulation of leptin release from human adipocytes using the model of in vitro differentiated adipocytes. For this purpose, it was necessary to demonstrate the presence of the three b-adrenergic receptor subtypes as well as their functional role in terms of stimulation of lipolysis in cultured human adipocytes.
Materials and methods

Materials
Collagenase CLS type 1 was obtained from Worthington (Freehold, NJ, USA); human insulin and cortisol were kindly donated by Hoechst Marrion Roussel (Frankfurt, Germany); culture media were obtained from Gibco (Berlin, Germany); isoproterenol, dobutamine, fenoterol, propranolol, and gentamycin were purchased from Sigma (Munich, Germany). BRL 37344 was obtained from RBI (Natick, MA, USA) and CGP 12177 was a gift from Ciba-Geigy (Basel, Switzerland). Superscript RT reverse transcriptase, random hexamers, Taq polymerase, PCR buffer, dCTP, dGTC, dTTP, dATP were obtained from Gibco/BRL (Berlin, Germany); for sequencing of the transcripts we used the ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction Kit from Perkin Elmer (Weiterstadt, Germany). Troglitazone was kindly provided by Sankyo (Munich, Germany). All other chemicals were from Boehringer (Mannheim, Germany) or Merck (Darmstadt, Germany). Sterile plasticware for tissue culture was purchased from Flow Laboratories (Irvine, Strathclyde, UK).
Subjects
Subcutaneous adipose tissue samples (50 to 100 g wet weight) were obtained from 9 normal-weight young females (body mass index (BMI) < 27 kg/m; age 31 6 8 years) undergoing elective mammary reduction. All subjects were of Caucasian origin. They were otherwise healthy according to clinical examination and laboratory tests and did not take any medication. Informed consent was obtained from the patients and the use of the adipose tissue for scienti®c studies was approved by the Ethical Committee of the Heinrich-Heine-University.
Isolation and in vitro differentiation of the stromal cell fraction from human adipose tissue After removal, the adipose tissue samples were immediately transported to the laboratory in DMEM/F12 medium. The stromal cell fraction was isolated by collagenase digestion according to the method described recently with some minor modi®cations (26) . Brie¯y, the fat specimens were cut into small pieces (1±2 mm 3 ) under sterile conditions and incubated in a collagenase solution (0.5 mg collagenase per ml phosphate-buffered saline (PBS) containing 20 mg/ml bovine serum albumin) for approximately 90 min in a shaking waterbath at 37 8C. After removal of the¯oating adipocyte fraction and a short centrifugation at 200 g, the sedimented stromal cells were resuspended in an erythrocyte lyzing buffer containing 154 mmol/l NH 4 Cl, 5.7 mmol/l K 2 HPO 4 and 0.1 mmol/l EDTA for 10 min to remove contaminating red blood cells. Finally, the dispersed cell material was ®ltered through a nylon mesh of 150 mm pore size. After repeated washing steps, the stromal cells were inoculated in a medium consisting of DMEM/Ham's F12 (v/v, 1:1) supplemented with 10% fetal calf serum. After 16 to 20 h for cell attachment, cultures were washed two times with PBS to remove non-adhering cells, cell detritus and serum. Cells were then refed with a serum-free medium consisting of DMEM/Ham's F12 (v/v, 1:1) supplemented with 15 mmol/l NaHCO 3 , 15 mmol/l Hepes, 33 mmol/l biotin, 17 mmol/l pantothenate, 10 mg/ml human transferrin and 50 mg/ml gentamycin. To induce adipose differentiation, the medium was also supplemented with adipogenic factors including 66 nmol/l insulin, 100 nmol/l cortisol, 0.2 nmol/l tri-iodothyronine and, for the ®rst three days, with 1 mg/ml troglitazone. The culture medium was changed 3 times per week. Full adipose differentiation was obtained after 16 days in culture with 50±70% of cells developing the adipocyte phenotype. These in vitro differentiated fat cells were used to study the effects of exposure to b-adrenoceptor agonists on leptin secretion into the culture medium.
RNA preparation and RT-PCR
Total RNA from cultured cells was prepared according to the method described by Chomczynski & Sacchi (27) . After incubation with the respective b-adrenoceptor agonist for 24 h, cells were harvested in TRIzol (Life Technologies, Eggenstein, Germany) and 200 ml choroform were added. After centrifugation, the aqueous phase was mixed with an equal volume of isopropyl alcohol. After 12 h at À20 8C, the RNA was pelleted for 15 min at 10 000 g, redissolved in LiCl 4 , washed twice with 70% ethanol, dried and redisolved in H 2 O. To exclude contamination by genomic DNA, a DNAse digestion (Promega, Madison, WI, USA) was performed according to the instructions of the manufacturer. The total RNA was diluted to 0.2 mg/ml in H 2 O, and ®rst strand cDNA prepared using 1 mg total RNA, Superscript RT reverse transcriptase, and random hexamers, according to the manufacturer's instructions.
Qualitative RT-PCR cDNA was diluted 1:8 with H 2 O, and PCR was carried out using 8.75 ml diluted cDNA and a PCR reaction mix containing 2.0 U Taq polymerase in its 1´buffer, 200 mmol/l dCTP, dGTP, dTTP, and dATP, and 500 pmol/l of each primer in a 25 ml volume with 50 ml mineral oil. PCR conditions were a denaturation step at 95 8C for 1 min followed by 33 
Measurement of glycerol and leptin concentration in the culture medium
Glycerol release and accumulation in the culture medium was used as an index of lipolysis. The measurement was carried out using a bioluminescent assay developed by Hellmer et al. (28) using commercially available solutions (BioThema AB, Dalaro È, Sweden). Leptin was measured in the medium using a speci®c highly sensitive radioimmunoassay (RIA) as described recently (29) . The intra-and interassay coef®cients of variation of the leptin RIA were 0.8% and 8.5% respectively.
Statistical analysis
Results are expressed as means 6 S.E.M. Differences between groups were tested using Student's t-test for paired data. Differences with a P value < 0.05 were regarded as signi®cant.
Results
Expression of b-adrenergic receptors and lipolytic response to agonists in in vitro differentiated human adipocytes First, to address the question of whether in vitro differentiated human adipocytes express the full lipolytic system, we examined the presence of the three b-adrenoceptor subtypes in differentiated fat cells. By using a qualitative RT-PCR technique we were able to demonstrate speci®c transcripts for the three subtypes according to transcript length and sequence (Fig. 1) .
In order to assess the functional role of the three receptors, we studied the effect of speci®c b-adrenoceptor agonists on lipolysis. As depicted in Fig. 2 , the non-selective agonist, isoproterenol, was found to induce a dose-dependent release of glycerol into the culture medium after a 12-h exposure. Similar effects were observed for the selective b 1 -agonist, dobutamine, the b 2 -agonist, fenoterol, the b 3 -adrenoceptor agonist CGP 12177 and BRL 37344 (Fig. 2) . At a concentration of 10 À6 mol/l for 12 h, isoproterenol caused a 6.3-fold increase in glycerol concentration above controls. The respective increase for dobutamine was 5.5-fold, for fenoterol 4.4-fold, for BRL 37344 6.3-fold and for CGP 12177 5.2-fold (Fig. 2) . Similar data were obtained when cells were exposed to the b-adrenoceptor agonists for 4 and 24 h respectively (data not shown). Figure 3 shows the time-course of leptin secretion into the culture medium in the absence and presence of 10 À7 mol/l isoproterenol. After 4 and 24 h respectively there was a statistically signi®cant reduction of leptin accumulation in the medium after exposure to isoproterenol. After the 4-h incubation, leptin concentration was reduced by 35% (P < 0.05) and after a 24-h exposure by 34% (P < 0.01). The inhibitory effect of isoproterenol was independent of the presence of troglitazone during the initial three days of culture for induction of adipose differentiation. However, in the presence of troglitazone the differentiation rate was clearly higher than in those without the thiazolidinedione (data not shown). Figure 4 demonstrates the dose±response relationship between isoproterenol and leptin release. A signi®-cant reduction of leptin release was already detectable at a concentration of 10 À8 mol/l isoproterenol after a 24-h incubation. In the presence of 10 À6 mol/l dobutamine for 24 h, leptin concentration was reduced by 25% (P < 0.05) (Fig. 5) . A smaller but still signi®cant reduction by 16% was seen after a 24-h exposure to 10 À6 mol/l fenoterol (P < 0.05) (Fig. 5) . In contrast, the two b 3 -adrenoceptor agonists, BRL 37344 and CGP 12177, were without an effect on leptin release (Fig. 5) indicating that the b 3 -adrenoceptors did not contribute to the suppression of leptin in human adipose tissue. This conclusion is also substantiated by another experiment (n = 4) where cells were incubated with 10 À7 mol/l propranolol and simultaneously with 10 À7 mol/l isoproterenol. The presence of propranolol was found to completely prevent the inhibitory effect of isoproterenol on leptin secretion (10 À7 mol/l isoproterenol for 24 h: 63.3 6 6.4% of control, P < 0.001; 10 À7 mol/l propranolol and 10 À7 mol/l isoproterenol: 95.0 6 4.5% of control), also arguing against a role of b 3 -adrenoceptors in the regulation of leptin secretion from human adipocytes.
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www.eje.org Figure 2 Dose-dependent effect of selected b-adrenoceptor agonists on glycerol release into the culture medium from in vitro differentiated human subcutaneous adipocytes on day 18. Cells were exposed to the agonists for 12 h. Results are means 6 S.E.M. of three separate experiments evaluated by Student's t-test for paired data. *P < 0.05, **P < 0.01, compared with control (C). Figure 3 Time-course of the effect of isoproterenol on leptin release into the culture medium of in vitro differentiated human adipocytes. Cells were exposed to 10 À7 mol/l isoproterenol for the time intervals indicated. Results are means 6 S.E.M. of four separate experiments in triplicate evaluated by Student's t-test for paired data. C, control (no isoproterenol).
Discussion
The results of these experiments clearly show that the non-selective b-adrenoceptor agonist, isoproterenol, exerts an inhibitory action on leptin protein release from cultured human adipocytes from young normalweight females. This effect was observed in the presence of insulin in the culture medium. The inhibition of leptin release from human adipocytes by isoproterenol was time-and dose-dependent and it is important to note that this effect was rapid and had already reached statistical signi®cance after 4 h.
These data are in good agreement with the results from a recent study by Ricci & Fried (23) who also found a decrease of leptin secretion and steady-state mRNA levels in adipose tissue from obese humans after exposure to isoproterenol. Furthermore, in this and other studies a decrease of leptin protein by catecholamines was also shown for omental adipose tissue (21, 23) which is another, but less important source of circulating leptin in humans (30) .
In view of pronounced differences in the BMI of the donors and the culture conditions between the study of Ricci & Fried (23) and our study, these results indicate that the inhibitory effect of isoproterenol is independent of the relative weight of the donor and of the experimental conditions.
In additional experiments, we also addressed the question of which b-adrenergic receptors contribute to this suppression. Our results suggest that the isoproterenol-induced suppression of leptin production is mediated via b 1 -and b 2 -adrenoceptors, although the b 3 -adrenoceptor subtype was clearly detectable at the mRNA level using a qualitative RT-PCR technique. However, the two selective b 3 -adrenoceptor agonists, BRL 37344 and CGP 12177, despite their possible interaction with other adrenoceptor subtypes (31) were unable to suppress leptin secretion and mRNA expression.
This ®nding is in clear contrast to the results of earlier reports in various animal models of obesity, and in clonal cell lines from rodent origin. In these studies, it was shown that the inhibitory effect of catecholamines was mainly mediated via the b 3 -adrenergic receptor which is the predominant b-adrenoceptor subtype in rodents (31) . For instance, Moinat et al. (10) showed that administration of a b 3 -adrenoceptor agonist inhibits leptin expression in white and brown adipose tissue of lean Zucker rats. Similar ®ndings were also reported by other groups (13±16). Figure 4 Dose±response relationship of the effect of isoproterenol on leptin release into the culture medium of in vitro differentiated human adipocytes. Cells were exposed to isoproterenol for 24 h. Results are means 6 S.E.M. of three separate experiments in triplicate evaluated by Student's t-test for paired data. *P < 0.05, compared with control (C). Figure 5 Effect of selective b-adrenoceptor agonists on leptin release into the culture medium of in vitro differentiated human adipocytes. Cells were exposed to the agonists for 24 h. Each agonist was used at a concentration of 10 À6 mol/l. Results are means 6 S.E.M. of six separate experiments in triplicate evaluated by Student's t-test for paired data. *P < 0.05, compared with control (C).
In cultured isolated rat adipocytes, isoproterenol and, less ef®ciently, a b 3 -adrenoceptor agonist decreased leptin mRNA expression and secretion into the medium (11) . This study also established that addition of dibutyryl cAMP mimicked this effect suggesting that the effect of b 3 -adrenoceptor agonists is exerted by its classical receptor pathway (11, 14, 16) . Similar ®ndings were reported for the 3T3-L1 adipocyte cell-line, where isoproterenol also potently reduced leptin mRNA levels, with a maximum effect at 10 À7 mol/l. In addition, propranolol was found to partially block this inhibition (12) .
According to our results incubation of human adipocytes with b 3 -adrenoceptor agonists did not affect leptin release despite a potent stimulation of lipolysis. This ®nding may indicate that regulation of leptin release by catecholamines is not linked to the lipolytic pathway and may involve other, not yet identi®ed, mechanisms. The physiological role of the b 3 -adrenoceptor in human adipose tissue is still a matter of debate, as controversial ®ndings have been reported for both the expression and function of this subtype in humans (32±35).
In conclusion, our experiments suggest an acute inhibitory effect of catecholamines on leptin secretion from cultured human adipocytes via b 1 -and b 2 -adrenoceptor agonists. In contrast to animal studies, the b 3 -adrenergic receptor subtype, although detectable and functionally active in cultured human adipocytes, does not appear to be involved in the inhibition of leptin expression.
